Skip to main navigation Skip to search Skip to main content

DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies

  • DuTOC scientific committee
  • , W K de Jong*
  • , F T A van der Velde
  • , A Keijser
  • , H J M Groen
  • , A S R van Lindert
  • , G R Vink
  • , L E L Hendriks
  • , M M van den Heuvel
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Downloads (Pure)

Abstract

The Dutch Thoracic Oncology Cohort (DuTOC) is a nationwide cohort for patients with thoracic malignancies collecting patient characteristics, quality of life and biomaterials after informed consent of the patient. With this data and material DuTOC is a solid infrastructure for retrospective and prospective studies involving treatment, (molecular) diagnostics, quality control, biomarkers and translational research and quality of life. DuTOC is initiated by the Dutch Association of Pulmonologists and is a collaboration of all clinicians involved in cancer-care and other stakeholders in the field of thoracic malignancies such as patient advocacies, health regulatory agencies, cancer registries and pharmaceutical companies. DuTOC has the ambition to automate real-time data acquisition. This minimizes the workload of the research staff and facilitates the transition to a self-learning health care system based on real-time data, incorporating long-term longitudinal assessment of patient reported outcome measurements. Therefore, DuTOC will play a crucial role in the improvement of the care for patients with thoracic malignancies.

Original languageEnglish
Article number108728
Number of pages4
JournalLung Cancer
Volume208
Early online date26-Aug-2025
DOIs
Publication statusPublished - Oct-2025

Fingerprint

Dive into the research topics of 'DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies'. Together they form a unique fingerprint.

Cite this